

RECOMMENDATIONS

1.

Prospectivelongitudinalstudiesformeasuringserumresistin levelsinpregnantfemales,especiallythoseatriskofpre-eclampsia,arerecommendedtoevaluateitsclinicalutilityasamarkerforpredictionofthedisease.Thiswillhelpindevelopingnovelstrategiesforearlymanagementofpre-eclampticpatients.

2.

FurtherevaluationofresistinanditsrelationshipoutertinearteryDopplerandothermaternalserummarkersisalsorecommended.

3.

Furtherstudiesareneededtoclarifytheoriginoftheelevationsinresistininpatientswithpreeclampsiaandtheroleofresistinint hepato-physiologyofpreeclampsia.

4.

Futureinvestigationisneededtodeterminewhetherthedifferentgeneticexpressionofmonocytesisrelatedtocirculatingresistinconcentrationsinwomenwithpre-eclampsia.

References

- Adeghate, E. (2004):** An update on the biology and physiology of resistin. *Cell. Mol. Life Sci.*; (61)(19-20) 2485-96.
- Adya, R.; Tan, B.K.; Punn, A.; Chen, J. and Randeve, HS. (2008):** Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. *Cardiovasc Res.*; 78: 356-65.
- Akdeniz, N.; Kuyumcuoglu,U.; Kale,A. and Kale,E. (2011):** Resistin may not associate with gestational diabetes mellitus although insulin resistance. *Clin. Exp. Obstet Gynecol.*; 38: 236–8.
- Al-Harithy, R.N. and Al-Ghafari, AB. (2010):** Resistin in human colon cancer. Increased expression independently of resistin promoter C-180G genotype. *Saudi Med J.*; 31: 495-500.
- AL-RefaiA. (2012):** Evaluation of Serum Levels of the Adipokines Chemerin and Resistin in Preeclampsia. *Life Sci J*; 9(4): 5143-55.
- Al-Safi, Z.; Imudia, A.N. and Filetti, LC. (2011):** Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. *Obstet Gynecol.*; 118(5): 1102-7.

- American College of Obstetrics and Gynecology (ACOG) Practice Bulletin (2007):** Diagnosis and management of pre-eclampsia and eclampsia. *Obstet. Gynecol.*; 99: 159-67.
- American Diabetes Association (2014):** Diagnosis and classification of diabetes mellitus. *Diabetes Care*; 37(Suppl. 1): S81–S90.
- Andrus, S.S. and Wolfson, A.B. (2010):** Postpartum preeclampsia occurring after resolution of antepartum preeclampsia. *J Emerg Med.*; 38(2): 168-70.
- Antuna-Puente, B.; Faraj, M. and Karelis, A.D. (2008):** HOMA or QUICKI: is it useful to test the reproducibility of formulas?. *Diabetes Metab.*; 34(3): 294-6.
- Arase, Y.; Suzuki, F. and Suzuki, Y. (2009):** Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. *Hepatology*; 49: 739–44.
- Arikan, D.C.; Bellamy, L. and Williams, D. (2009):** Type 2 diabetes mellitus after gestational diabetes: a systematic review. *Lancet*; 373: 1773–9.
- Azuma, K.; Katsukawa, F.; Oguchi, S.; Murata, M.; Yamazaki, H. and Shimada, A. (2003):** Correlation between serum resistin level and adiposity in obese individuals. *Obes. Res.* Aug; (11)8:997-1001.
- Barker, D.J. (2006):** The developmental origins of well-being. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.*; 359: 1359-66.

- Baumann, M.U.; Nick, A.B.; Daniel, V. and Surbek, A. (2010):** Markers for predicting pre-eclampsia. *Obstet. Gynecol.*; 28: 227-44.
- Baweja, S.; Kent, A.; Masterson, R.; Roberts, S. and McMahon, L. (2011):** Prediction of pre-eclampsia in early pregnancy by estimating the spot urinary albumin: creatinine ratio using high-performance liquid chromatography. *BJOG.*; 118(9): 1126-32.
- Berkane, N.; Lefevre, G. and Hertig, A. (2007):** Angiogenic factors in pre-eclampsia: so complex, so simple. *Nephrol. Dial. Transplant*; 22: 2753-6.
- Bernabeu C.; Lopez-Novoa JM. and Quintanilla, M. (2009):** The emerging role of TGF-beta superfamily coreceptors in cancer. *Biochim Biophys Acta*; 1792: 954-73.
- Bersinger, N.A. and Odegard, R.A. (2004):** Early biochemical detection of pre-eclampsia: the role of placental proteins. *Immunoanal. Biol. Spec.*; 19: 47-53.
- Bertolani, C.; Sancho-Bru, P.; Failli, P.; Bataller, R.; Aleffi, S.; DeFranco, R.; Mazzinghi, B.; Romagnani, P.; Milani, S. and Gine's, P.(2006):** Resistin as an Intrahepatic Cytokine. The overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. *American Journal of Pathology*; 169 (6): 2042-53.

- Bokarewa, M.; Nagaev, I.; Dahlberg, L.; Smith, U. and Tarkowski, A. (2005):** Resistin, an adipokine with potent proinflammatory properties. *J Immunol*; 174: 5789–95.
- Bossowski A.; Sawicka B. and Szalecki M. (2010):** Analysis of serum adiponectin, resistin and leptin levels in children and adolescents with autoimmune thyroid disorders. *J Pediatr Endocrinol Metab.*; 23(4): 369–77.
- Bourke, G.; Daly, L.E. and McGilvary, J. (1985):** In: *Basic and Clinical Biostatistics*. 2nd edition. B.D., Saunders and R.G., Trapp (Eds). Prentice-Hall International Inc., USA.;516-20.
- Buchbinder, A.; Sibai, B.M. and Caritis, S. (2008):** Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild pre-eclampsia. *Am. J. Obstet. Gynecol.*; 186: 66-71.
- Burton, G.J. and Hung, T.H. (2008):** Hypoxia-reoxygenation; A potential source of placental oxidative stress in normal pregnancy and pre-eclampsia. *Fetal Maternal Medicine Rev.*; 14: 97-117.
- Buse, J.B.; Polonsky, K.S. and Burant, C.F. (2008):** Type 2 Diabetes mellitus in Williams's textbook of endocrinology. Edition (11) Kronenberg H.M., Melmed S., Polonsky K.S. and Larsen P.R. (eds). W.B Saunders Company, Elsevier; 30: 1329-89.

- Canini, G.; Daty, L.E. and McGilvary, J. (2008):** Interpretation and uses of pregnancy associated plasma protein A. Blackwell Scientific Publications.; 22: 650-67.
- Cedergren, M.I. (2010):** Maternal morbid obesity and the risk of adverse pregnancy outcome. *Obstet. Gynecol.*; 103: 219.
- Chappell, L.; Sed, P.; Briley, A.; Kelly, A.; Lee, R. and Hunt, B. (2008):** Effects of anti-oxidants on the occurrence of pre-eclampsia in women at increased risk: A randomized trial. *Lancet.*; 354: 810-6.
- Chen, D.; Dong, M.; Fang, Q.; He, J.; Wang, Z. and Yang, X. (2003):** Alterations of serum resistin in normal pregnancy and pre-eclampsia. *Clinical Science*; 108: 81-4.
- Cheng, A.Y. and Leiter, L.A. (2006):** Metabolic syndrome under fire: weighing in on the truth. *Can J Cardiol.*; 22(5): 379-82.
- Chiamolera, M.I. and Wondisford, F.E. (2009):** Minireview: Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism. *Endocrinology*; 150(3): 1091–6.
- Chung, S.S.; Choi H.H.; Kim K.W.; Cho, Y.M.; Lee, H.K. and Park, K.S. (2005):** Regulation of human resistin gene expression in cell systems: an important role of stimulatory protein1-interaction with a common promoter polymorphic site. *Diabetologia.*; (48) 6: 1150-8.
- Coll, A.P.; Farooqi, I.S. and O’Rahilly, S. (2008):** The hormonal control of food intake. *Cell.*; 129(2): 251-62.

- Coomarasamy, A.; Papaioannou, S.; Gee, H. and Khan, K.S (2008):** Aspirin for the prevention of pre-eclampsia in women with abnormal uterine artery Doppler: a meta-analysis. *Obstet. Gynecol.*; 98(5 pt 1): 861-6.
- Cooray, S.D.; Edmonds, S.M.; Tong, S.; Samarasekera, S.P. and Whitehead, C.L. (2011):** Characterization of symptoms immediately preceding eclampsia. *Obstet Gynecol.*; 118(5): 995-9.
- Csaba, G.; Kovacs, P. and Pallinger, E. (2003):** Gender differences in the histamine and serotonin content of blood, peritoneal and thymic cells: a comparison with mast cells. *Cell Biol. Int.*; (27)4:387-9.
- Cunningham, F.G. (2005):** Liver disease complicating pregnancy. In *Williams Obstetrics*, 19th ed. M.Longmore, I.B.Wilkinson, and S.Rajagopalan, (Eds). Oxford University Press Inc. New York.;90-163.
- Czech, M.P.; Erwin, J.L. and Sleeman, M.W. (2000):** Insulin action on glucose transport. *Diabetes mellitus in fundamental and clinical text* (2nd edition), Leroith D., Olefsky J.M. Lippincott and Williams (eds). Awolter Kluwer, Philadelphia; 264-73.
- D'Ippolito, S.; Tersgni, C.; Scambia, G. and DiSimone, N. (2012):** Adipokines, an adipose tissue and placental product with biological functions during pregnancy. *Biofactors*; 38: 14–23.

Daskalopoulou, S.S.; Athyros, V.G.; Kolovou, G.D.; Anagnostopoulou, K.K. and Mikhailidis, D.P. (2006): Definitions of metabolic syndrome: Where are we now? *Curr Vasc Pharmacol.*; 4(3): 185-97.

De Stefano, V.; Rossi, E. and Leone, G. (2008): Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. *Semin. Vasc. Med.*; 3: 47-60.

De Taeye, B.; Smith, L.H. and Vaughan, D.E. (2005): Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. *Curr Opin Pharmacol.*; 5(2): 149-54.

Dekker, G. and Sibai, B. (2009): Primary, secondary, and tertiary prevention of pre-eclampsia. *Lancet*; 357: 209-15.

Demirci, O.; Tug-rul, A.; Dolgun, N.; Sözen, H. and Eren, S. (2011): Serum lipids level assessed in early pregnancy and risk of pre-eclampsia. *J. Obstet. Gynaecol. Res.*; 37: 1427-32.

Devaraj, S.; Singh, U. and Jialal I. (2009): Human C-reactive protein and the metabolic syndrome. *Curr Opin Lipidol.*; 20(3): 182-9.

Diamant, M. and Tushuizen, ME. (2006): The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD. *Curr Diab Rep.*; 6(4): 279-86.

Dushay, J. and Abrahamson, M.J. (2005): Insulin resistance and type 2 diabetes: a comprehensive review. *Medscape*

Today [serial online]. Apr 8; Available at <http://www.medscape.com/viewprogram/3942>.

Edward, K. and Schultz, M.D. (1999): Selection and Interpretation of Laboratory Procedures. In: Tietz Textbook of Clinical Chemistry. 3rd edition. C.A. Burtis and E.R. Ashwood (Eds). Philadelphia, W.B. Saunders Co.; 310-9.

El Gawad, SS.; El Kenawy, F.; Mousa, AA. and Omar, A.A. (2012): Plasma levels of resistin and ghrelin before and after treatment in patients with hyperthyroidism. *Endoc Pract.*; 18(3): 376–81.

Essah, P.A. and Nestler, J.E. (2006): The metabolic syndrome in polycystic ovary syndrome. *J Endocrinol Invest.*; 29(3):270-80.

Fauci, AS.; Braunwald, E. and Kasper, DL. (2008): Harrison's Principles of Internal Medicine. 17th ed. New York, NY: New York, NY.

Filkova, M.; Haluzik, M.; Gay, S. and Senolt, L. (2009): The role of resistin as a regulator of inflammation: Implications for various human pathologies. *Clin Immunol.*; 133(2): 157–70.

Flier, J.S.; Kahn, C.R. and Roth, J. (1979): Receptors, antireceptor antibodies and mechanisms of insulin resistance; *N. Engl. J. Med.*; 8: 413-9.

Florez, H.; Castillo-Florez, S.; Mendez, A.; Casanova-Romero, P.; Larreal-Urdaneta, C. and Lee, D. (2006): C-reactive

protein is elevated in obese patients with the metabolic syndrome. *Diabetes Res Clin Pract.*; 71(1): 92-100.

Fogiel, M. (1986): Non-parametric methods. In: *Statistical Problem Solver*. 2nd edition. M. Fogiel (Eds.) New York, Research & Education Association; 864.

Fujinami, A.; Ohta, K.; Kitada, N.; Kuno, S. and Ohta M. (2006): Resistin concentration in murine adipose tissue and serum measured by a new enzyme immunoassay. *Obesity.*; 14: 199-205.

Fuke, Y.; Fujita, T.; Satomura, A.; Wada, Y. and Matsumoto K.(2010): Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. *Diabetes Technol Ther*; 12(5):393-8.

Garten, A.; Petzold, S.; Korner, A.; Imai, S. and Kiess, W. (2009): Nampt: linking NAD biology, metabolism and cancer. *Trends Endocrinol Metab.*; 20: 130-8.

Gerhardt, A.; Goecke, T. W.; Beckmann, M. W; Wagner, K. J. and Zotz, R.B. (2010): (The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe pre-eclampsia. *Journal of Thrombosis and Haemostasis.*; (6): 686-91.

Grant PJ. (2005): Inflammatory, atherothrombotic aspects of type 2 diabetes. *Curr Med Res Opin.*; 21 Suppl 1: S5-12.

- Gu, S.; Lewis, D. F. and Wang, Y. (2008):** Placental Productions and Expressions of Soluble Endoglin, Soluble fms-Like Tyrosine Kinase Receptor-1, and Placental Growth Factor in Normal and Pre-eclamptic Pregnancies. *J. Clin. Endocrinol. Metab.*; 93(1): 260–6.
- Gül, G.; Onur, E.; Nazli, G.K.; Hacer, C.; Yasar, A. and Berrin, D. (2012):** The relation of obesity with serum resistin levels in smoker and nonsmokers. *J. Res. Med. Sci.*; 17: 119–22.
- Harskamp, R.E. and Zeeman, G.G. (2007):** Preeclampsia: at risk for remote cardiovascular disease. *Am J Med Sci.*; 334(4): 291-5.
- Hasanzadeh, Y.J.; Williamson, R.A. and Chen, K. (2008):** Plasma homocysteine concentration is increased in pre-eclampsia.; 38: 992–6.
- Haugen, F.; Ranheim, T.; Harsem, N.K.; Lips, E.; Staff, A.C. and Drevon, C.A. (2006):** Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression. *Am J Physiol Endocrinol Metab.*; 290; E326–33.
- Heilbronn L., Rood J. and Janderova L. (2004):** Relationship between serum resistin concentrations and insulin resistance in nonobese, and obese diabetic subjects. *J. Clin. Endocrinol. Metab.*; 89: 1844–8.

Herman, W.H.; Hoerger, T.J.; Brandle, M.; Hicks, K.; Sorensen, S. and Zhang, P. (2005): The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. *Ann Intern Med.*; 142(5): 23-32.

Hirschler, V.; Ruiz, A.; Romero, T.; Dalamon, R. and Molinari, C. (2009): Comparison of different anthropometric indices for identifying insulin resistance in schoolchildren. *Diabetes Technol Ther.*; 11(9): 615-21.

Hivert, M.F.M.; Anning, A.K.; McAteer, J.B.; Dupuis, J.; Fox, C.S. and Cupples, L.A. (2009): Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. *Diabetes.*; 58: 750–6.

Hofmeyr, G.J.; Atallah, A.N. and Duley, L. (2010): Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane, database, Syst. Rev.*; 19(3): 1059.

Holcomb, I.N.; Kabakoff, R.C.; Chan, B.; Baker, T.W.; Gurney, A.; Henzel, W.; Nelson, C.; Lowman, H.B.; Wright, B.D. and Skelton, N.J. (2000): FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family, *EMBO J.*; 19: 4046–55.

Holmes, V.A.; Young, I.S.; Patterson, C.C.; Maresh, M.J.; Pearson, D.W. and Walker, J.D. (2013): The Role of

Angiogenic and Antiangiogenic Factors in the Second Trimester in the Prediction of Preeclampsia in Pregnant Women With Type 1 Diabetes. *Diabetes Care*; 6 2013.

Holzgreve, W.; Li, J.J. and Steinborn, A. (2001): Elevation in erythroblast count in maternal blood before the onset of pre-eclampsia .*Am. J. Obstet. Gynecol.*; 184: 165-8.

Hug, C. and Lodish, H.F. (2005): The role of the adipocyte hormone adiponectin in cardiovascular disease. *Curr Opin Pharmacol.*; 5(2): 129-34.

Hulstein, J.; Van Runnard Heimel, P.J. and Franx, A. (2006): Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome.*J. Thromb. Haemost.*; 4 (12): 2569-75.

Iftikhar, J.; Benattar, C. and Audibert, F. (2008): Severe pre-eclampsia is associated with high inhibin A levels and normal leptin levels at 7 to 13 weeks into pregnancy . *Am. J. Obstet. Gynecol.*; 189: 1517-22.

Imai S. (2009): Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. *Curr Pharm Des.*; 15: 20-8.

Janke J.; Engeli S.; Gorzelniak K.; Luft F.C. and Sharma A.M. (2002): Resistin gene expression in human adipocytes is not related to insulin resistance. *Obes. Res.*; 1:1-5.

Jayagopal, V.; Kilpatrick, E.S.; Holding, S.; Jennings, P.E. and Atkin, SL. (2005): Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. *J Clin Endocrinol Metab.*; 90(2): 729-31.

Jensterle, M.; Janez, A.; Mlinar, B.; Marc, J.; Prezelj, J. and Pfeifer, M. (2008): Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. *Eur J Endocrinol.*; 158(6): 793-801.

Jenum, A.K.; Morkrid, K.; Sletner, L.; Vangen, S. and Nakstad, B. (2012): Impact of ethnicity on gestational diabetes identified with the WHO and the modified International Association of Diabetes and Pregnancy Study Groups criteria: a population-based cohort study. *Eur. J. Endocrinol.*; 166: 317–24.

John, J.H.; Ziebland, S.; Yudkin, P.; Roe, L.S. and Neil, H.A. (2008): Effects of fruit and vegetable consumption on plasma anti-oxidant concentrations and blood pressure: A randomized controlled trial. *Lancet*; 359: 1969-74.

Kahn, R.; Buse, J.; Ferrannini, E. and Stern, M. (2005): The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*; 28(9): 2289-304.

Kaplan, O.; Uzum, A.K. and Aral, H. (2012): Short Term Thyroidectomy-Induced Hypothyroidism Causes No

Change on Serum Adipokine Concentrations. *Endocr Pract.*; 1–19.

Kaur, J.; Adya, R.; Tan, BK.; Chen, J. and Randeve, H.S. (2010): Identification of chemerin receptor (Chem R23) in human endothelial angiogenesis. *Biochem Biophys Res Commun.*; 391: 1762-8.

Kawaguchi, T.; Ide T. and Taniguchi, E. (2007): Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. *Am J Gastroenterol.*; 102: 570–6.

Kim K.H.; Lee K.; Moon, Y.S. and Sul, H. S. (2001): A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. *J. Biol. Chem. Apri*; (276) 14: 11252-6.

Kim, J.A.; Wei, Y. and Sowers, J.R. (2008): Role of mitochondrial dysfunction in insulin resistance. *Circ Res.*; 102(4): 401-14.

Kim, S.R.; Bae, S.K.; Choi, K.S.; Park, S.Y.; Jun, H.O. and Lee J.Y. (2007): Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. *Biochem Biophys Res Commun.*; 357: 150-6.

Kiortsis, D.N.; Filippatos, T.D. and Elisaf, M.S. (2005): The effects of orlistat on metabolic parameters and other cardiovascular risk factors. *Diabetes Metab.*; 31(1): 15-22.

- Klok, M.D.; Jakobsdottir, S. and Drent, M.L. (2007):** The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. *Obes Rev.*; 8(1): 21-34.
- Knight, M.; Kurinczuk, J.J.; Spark, P. and Brocklehurst, P. (2010):** Extreme obesity in pregnancy in the United Kingdom. *Obstet Gynecol.*; 115(5): 989-97.
- Kralisch, S.; Stepan, H.; Kratzsch, J.; Verlohren, M.; Verlohren, H.J. and Drynd, K. (2009):** Serum levels of adipocyte fatty acid binding protein are increased in gestational diabetes mellitus. *Eur. J. Endocrinol.*; 160: 33–8.
- Krassas, G.E.; Pontikides N. and Loustis K. (2006):** Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters. *J Endocrinol Invest.*; 29(7): 606–12.
- Krecki R.; Krzeminska-Pakula M. and Peruga JZ.(2011):** Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. *Med Sci Monit.*; 17(1): CR26–32.
- Lappas, M.; Permezel M. and Rice, G.E. (2004):** Release of pro-inflammatory cytokines and 8 -isoprostane from placenta, adipose tissue and skeletal muscle from normal pregnant women and women with gestational diabetes

mellitus. *Journal of Clinical Endocrinology and Metabolism.*; 89(11): 5627–33.

Laresgoiti-Servitje E.; Gómez-López N. and Olson, D.M. (2010): "An immunological insight into the origins of pre-eclampsia". *Hum Reprod Update*; 16 (5): 510–24.

Lau, C.H. and Muniandy, S. (2011): Resistin gene polymorphisms in association with their respective adipokine levels. *Ann. Hum. Genet.*; 75: 370–82.

Laursen, J.I.; Sangi-Haghpeykar, H. and Gardner, N.O. (2001): Role of Pregnancy associated plasma protein A in diseases. *Am. J. Obstet. Gynecol.*; 188: 1241-3.

Lee, S.H.; Park, S.A.; Ko, S.H.; Yim, H.W.; Ahn, Y.B. and Yoon, KH. (2010): Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. *Metabolism.*; 59(2): 241-6.

Lee, W.J.; Lee, Y.C.; Ser, K.H.; Chen, J.C. and Chen, S.C. (2008): Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. *Obes Surg.*; 18(9): 1119-25.

Lee, YC.; Yang, YH.; Su, JH.; Chang, HL.; Hou, MF. and Yuan, SS. (2011): High visfatin expression in breast cancer tissue is associated with poor survival. *Cancer Epidemiol Biomarkers Prev.*; 20: 1892-901.

- Levine, R.J.; Maynard, S.E. and Qian, C. (2004):** Circulating angiogenic factors and the risk of pre-eclampsia .N. Engl. J. Med.; 350: 672-83.
- Li, Z.; Zhang, Y.; Ying, M. J.; Kapoun, A.M.; Shao, Q. and Lam, A. (2007):** Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of pre-eclampsia. Hypertension; 50: 686-92.
- Lisonkova, S.; Levine, R.J. and Joseph, KS. (2013):** Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol.; 209: (44): 541-4.
- Lutsey, P.L.; Steffen, L.M. and Stevens, J. (2008):** Dietary intake and the development of the metabolic syndrome: the Atherosclerosis Risk in Communities study. Circulation; 117(6): 754-61.
- Luvizotto RA.; Sibio MT. and Olimpio RM. (2011):** Supra-physiological triiodothyronine doses diminish leptin and adiponectin gene expression, but do not alter resistin expression in calorie restricted obese rats. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme; 43(7): 452-7.
- Lynch, A.; Murphy, J. and Gibb, R. (2010):** Interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG.; 456-62.

- Mackay, A.P.; Berg, C.J. and Atrash, H.K. (2009):** Pregnancy-related mortality from pre-eclampsia and eclampsia. *Obstet. Gynecol.*; 97: 533-8.
- MacReady, N. (2013):** A Step Closer to Predicting Preeclampsia Risk in Diabetes. Available at <http://www.medscape.com/viewarticle/809509>. Accessed August 20, 2013.
- Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, B.F. and Turner, R.C. (1985):** Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*; 28: 412–9.
- Maulik, D.** Doppler ultrasound in obstetrics and gynecology. Springer Verlag. (2005) ISBN: 3540230882.
- Maynard, S.E.; Venkatesha, S.; Thadhani, R. and Karumanchi, S.A. (2005):** Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of pre-eclampsia. *Pediatr. Res.*; 57 (5 pt2): 1R-7R.
- Meilleur, K.G.; Doumatey, A.; Huang, H.; Charles, B.; Chen, G. and Zhou, J. (2010):** Circulating adiponectin is associated with obesity and serum lipids in West Africans. *J Clin Endocrinol Metab.*; 95(7): 3517-21.
- Meyts, P.D. and Whittaker, J. (2002):** Molecular structure of the insulin receptor. Implications for drug design. *Nature*; 1: 769-83.

- Michelle, H.; Karumanchi, S. and Richard, L. (2007):** Pathophysiology of the Clinical Manifestations of Pre-eclampsia Clin. J. Am. Soc. Nephrol.; 2: 543-9.
- Migliacci, R. and Becattini, C. (2007):** Endothelial dysfunction in patients with spontaneous venous thromboembolism. Thromb. Haemost.; 97: 444-504.
- Moadab, M.H.; Kelishadi, R.; Hashemipour, M.; Amini, M. and Poursafa, P. (2010):** The prevalence of impaired fasting glucose and type 2 diabetes in a population-based sample of overweight/obese children in the Middle East. *Pediatr Diabetes.*; 11(2): 101-6.
- Moreno-Navarrete, J.M.; Catalán, V.; Ortega, F.; Gómez-Ambrosi, J.; Ricart, W. and Frühbeck, G. (2010):** Circulating omentin concentration increases after weight loss. *Nutr Metab (Lond)*; 7: 27.
- Mostello, D.; Jen Chang, J.; Allen J.; Luehr, L.; Shyken J. and Leet T. (2010):** Recurrent preeclampsia: the effect of weight change between pregnancies. *Obstet Gynecol.*; 116(3): 667-72. *pre-eclampsia. BJOG.*; 117(13): 1593-8.
- Moucari, R.; Asselah, T. and Cazals-Hatem, D. (2008):** Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. *Gastroenterology*; 134: 416–23.
- Muniyappa, R.; Lee, S.; Chen, H. and Quon, M.J. (2008):** Current approaches for assessing insulin sensitivity and

resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol Endocrinol Metab.*; 294(1):E15-26.

Nakajima, T.E.; Yamada, Y.; Hamano, T.; Furuta, K.; Gotoda, T. and Katai, H. (2009): Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. *J Gastroenterol.*; 44: 685-90.

Nanda, S.; Poon, L.C.; Acosta, I.C. and Nicolaidis, K.H. (2012): Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies. *Metabolism.*; 61: 699–705.

Nannipieri M.; Cecchetti F. and Anselmino M. (2009): Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and/or type 2 diabetes: effects of weight loss. *Int J Obes (Lond)*; 33(9): 1001–6.

National Committee for Clinical Laboratory Standards (2007): Routine Urine analysis and Collection, Transportation, and Preservation of Urine Specimens: Approved Guideline G.P. 16-A2. 2nd ed., Wayne, P.A., National Committee for Clinical Laboratory Standards.

Ngoc, N.T.; Merialdi, M.; Abdel-Aleem, H.; Carroli, G.; Purwar, M. and Zavaleta, N. (2006): Causes of stillbirths and early neonatal deaths: data from 7993 pregnancies in six developing countries. *Bull World Health Organ.*; 84(9): 699-705.

- Nissen, S.E. and Wolski, K. (2007):** Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med.*; 356(24): 2457-71.
- Page, E.W. (2010):** The relation between hydatid moles and the placental origin of pre-eclampsia. *Am. J. Obstet. Gynecol.*; 37: 291–3.
- Pantsulaia I.; Livshits G.; Trofimov S.; Kobylansky, E. (2007):** Genetic and environmental determinants of circulating resistin level in a community-based sample *Eur. J. Endocrinol.*; (156)1 pp: 129-135.
- Papageorghiou, A.T. and Campbell, S. (2006):** First trimester screening for pre-eclampsia. *Curr. Opin. Obstet. Gynecol.*;18: 594-600.
- Pasquali, R.; Patton, L.; Pagotto, U. and Gambineri, A. (2005):** Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. *Minerva Ginecol.*; 57(1): 79-85.
- Patel, L.; Buckels, A.C.; Kinghorn, I.J.; Murdock, P.R.; Holbrook J.D. and Plumpton C. (2003):** Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. *Biochem. Biophys. Res. Commun.*; 300(2): 472-6.
- Pazienza, V.; Clément, S. and Pugnale, P. (2007):** The hepatitis C virus core protein of genotypes 3a and 1b down-regulates

insulin receptor substrate 1 through genotype-specific mechanisms. *Hepatology*; 45: 1164–71.

Peleg, R.K.; Efrati, S. and Benbassat, C. (2008): The effect of levothyroxine on arterial stiffness and lipid profile in patients with subclinical hypothyroidism. *Thyroid.*; 18(8): 825–30.

Pinarbasi, P.L.; Peters, W.H. and Visser, W. (2007): A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia. *J. Med. Genet.*; 38: 234–7.

Powell, A.; Teichtahl, A.J.; Wluka, A.E. and Circuttini, F.M. (2005): Obesity: a preventable risk factor for large joint osteoarthritis which may act through biochemical factors. *Br J Sports Med*; 39: 4-5.

Pritchett, A.M.; Foreyt, J.P. and Mann, D.L. (2005): Treatment of the metabolic syndrome: the impact of lifestyle modification. *Curr Atheroscler Rep.*; 7(2): 95-102.

Quinn, C.E.; Hamilton, P.K.; Lockhart, C.J. and McVeigh, G.E. (2008): Thiazolidinediones: effects on insulin resistance and the cardiovascular system. *Br J Pharmacol.*; 153(4): 636-45.

Rajala, M.; Obici, S.; Scherer, P. and Rosseth, L. (2003): Adipose derived resistin and gut-derived resistin like molecule- β selectively impair insulin action on glucose protection. *J. Clin. Invest.*; 111: 225-30.

Rasouli, N.; Raue, U.; Miles, L.M.; Lu, T.; Di Gregorio, G.B. and Elbein, S.C. (2005): Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. *Am J Physiol Endocrinol Metab.*; 288(5): E930-4.

Reaven, GM. (2006): The metabolic syndrome: is this diagnosis necessary? *Am J Clin Nutr.*; 83(6): 1237-47.

Redman, C.W. and Sargent, I.L. (2005): Latest advances in understanding preeclampsia. *Science*; 308: 1592-4.

Redman, C.W. and Sargent, I.L. (2010): Pre-eclampsia, the placenta, and the maternal systemic inflammatory response. *Placenta*; 24: S21-S7.

Refsum, H.; Smith, A.D.; Ueland P.M.; Nexø, E. and Clarke, R. (2004): Facts and recommendations about total homocysteine determinations: an expert opinion. *Clin Chem*; 50: 3-32.

Reilly, M.P.; Lehrke, M.; Wolfe, M.L.; Rohatgi, A.; Lazar, M.A. and Rader, D.J. (2005): Resistin is an inflammatory marker of atherosclerosis in humans, *Circulation*; 111: 932–9.

Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy (2007): *Am. J. Obstet. Gynecol.*; 183: S1-22.

Roberts, J.M.; Pearson, G.; Cutler, J. and Lindheimer, M. (2010): Summary of the NHLBI working group on research

on hypertension during pregnancy. *Hypertension*; 41: 437-45.

Roberts, J.M.; Pearson, G.; Cutler, J. and Lindheimer, M. (2010): Summary of the NHLBI working group on research on hypertension during pregnancy. *Hypertension*; 41: 437-45.

Sacks, D.B. (2006): Diabetes mellitus in Teitz Text Book of clinical chemistry and molecular genetics (4th edition). Burtis C. A., Ashwood E. R. and Bruns D.E. (Eds). W.B Saunders Co, Philadelphia;2(25): 853-75.

Saira-Salahuddin, M.D.; Lee, Y. and Vadnais, M. (2007): Diagnostic utility of soluble fms-like tyrosine kinase-1 and soluble endoglin in hypertensive diseases of pregnancy. *Am. J. Obstet. Gynecol.*; 197: 28.e1-28.e6.

Saito, S.; Shiozaki, A.; Nakashima, A. and Sakai, M. (2007): The role of the immune system in pre-eclampsia. *Molecular Aspects of Medicine*; 28(2): 192-209.

Salonen, H.; Lichtenstein, P.; Lipworth, L. and Cnattingius, S. (2007): Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. *Am. J. Med. Genet.*; 91: 256–60.

Salpeter SR.; Buckley NS.; Kahn JA. and Salpeter EE. (2008): Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. *Am J Med.*; 121(2): 149-157.e2.

- Sarti, C. and Gallagher J. (2006):** The metabolic syndrome: prevalence, CHD risk, and treatment. *J Diabetes Complications*; 20(2): 121-32.
- Satheesh, K.K.; Sridhar, R.B. and Everett, F.M. (2008):** HELLP syndrome leading to a diagnosis of Pregnancy. *South. Med. J.*; 95(8): 934-45.
- Savino, A.; Pelliccia, P.; Chiarelli, F. and Mohn, A. (2010):** Obesity-related renal injury in childhood. *Horm Res Paediatr.*; 73(5): 303-11.
- Savidou, M.D.; Vallance, P.T. and Nicolaides, K.H. (2006):** Endothelial nitric oxide synthase gene polymorphism in pre-eclampsia. *Hypertension*; 38: 1289–93.
- Say, J.; Villar, L.; Gülmezoglu, M.; Merialdi, M.; Lindheimer, M. and Betran, A. (2007):** Eclampsia and pre-eclampsia: a worldwide health problem for 2000 years. London: RCOG Press; 57-72.
- Schulze, P.C.; Biolo, A.; Gopal, D.; Shahzad, K. and Balog J. (2011):** Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. *J Card Fail*; 17: 1004-11.
- Schwartz, R.B.; Feske, S.K.; Polak, J.F.; DeGirolami, U. and Repke, J.T. (2006):** Pre-eclampsia: Clinical and neuro-radiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. *Radiology*; 217: 371–6.

Sed, A.; Gonigal, S.; Gilmour, C.; Hubel, C.A. and Rajakumar, A. (2010): Effects of anti-oxidants on the occurrence of pre-eclampsia. *Placenta*; 29(6): 555-63.

Seely, E. W. and Solomon, C. G. (2003) Insulin resistance and its potential role in pregnancy-induced hypertension. *J. Clin. Endocrinol. Metab.*; 88: 2393–8.

Semple, R.K.; Cochran, E.K.; Soos, M.A.; Burling, K.A.; Savage, D.B. and Gorden, P. (2008): Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. *Diabetes Care.*; 31(5): 977-9.

Senna, Y. H.; Ueyama, T.; Mashimo, K.; Kangawa, N. and Minamino, N. (2008): Circulating Mature Adrenomedullin Is Related to Blood Volume in Full-Term Pregnancy. *Anesth. Analg.*; 101(6): 1816-20.

Seol, H.J.; Oh, M.J.; Yeo, M.K.; Kim, A.; Lee, E.S. and Kim, H.J. (2010): Comparison of Serum Levels and the Placental Expression of Resistin Between Patients with Preeclampsia and Normal Pregnant Women. *Hypertension in Pregnancy*; 29: 310–7.

Seow, K.M.; Juan, C.; Wu, L.; Hsu, Y.; Yang, W.; Tsia, Y. and Hwang, J. (2004): Serum and adipocyte resistin in polycystic ovary syndrome. *Human Reproduction*; 19: 48-53.

- Shackelford, R.E.; Bui, M.M.; Coppola, D. and Hakam, A. (2010):** Over-expression of nicotinamide phosphoribosyl transferase in ovarian cancers. *Int J Clin Exp Pathol.*; 3: 522-7.
- Shand, A.; Nassar, N.; Von Dadelszen, P.; Innis S. and Green, T. (2010):** Maternal vitamin D status in pregnancy and adverse pregnancy outcomes in a group at high risk for pre-eclampsia. *BJOG*; 117(13): 1593-8.
- Sharma, A. and Haldiya, S.S. (2002):** Insulin sensitivity in pre-eclampsia. *J. Assoc. Physicians India*; 50: 1022-7.
- Sharma, R.; Sharma, T.K. and Kaushik, G.G. (2011):** Subclinical hypothyroidism and its association with cardiovascular risk factors. *Clin Lab.*; 57(9-10): 719-24.
- Sharon, M.; Franklin, H.; Epstein, S. and Ananth, K. (2008):** Pre-eclampsia and Angiogenic Imbalance. *Annual Review of Medicine*; (59): 61-78.
- Sheiner, E. (2005):** Placental abruption in term pregnancies: clinical significance and obstetrical risk factors. *J. Matern. Fetal Neo. Med.*; 12: 45-49.
- Shih, KC.; Janckila, AJ.; Kwok, CF.; Ho, LT.; Chou, YC. and Chao, TY. (2010):** Effects of exercise on insulin sensitivity, inflammatory cytokines, and serum tartrate-resistant acid phosphatase 5a in obese Chinese male adolescents. *Metabolism*; 59(1): 144-51.

- Sibai, B.M. (2008):** Diagnosis and management of gestational hypertension and pre-eclampsia. *Obstet. Gynecol.*; 102: 181-92.
- Sibai, B.M. (2009):** Imitators of severe pre-eclampsia/eclampsia. *Clin. Perinatol.*; 31: 835– 52.
- Sifakis, X.Y.; Hoizgreve, W. and Hahn, S. (2009):** The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of pre-eclampsia. *Hypertens. Pregnancy*; 21: 77-83.
- Silha, J.; Krsek, M.; Skrha, J.; Sucharda, P.; Nyomba, B. and Murphy, L. (2003):** Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. *Eur. J. Endocrinol.*; 149: 331–5.
- Sjöholm, A. and Nyström, T. (2005):** Endothelial inflammation in insulin resistance. *Lancet*; 365(9459): 610-2.
- Sjöström, L. (2006):** Analysis of the XENDOS study (Xenical in the Prevention of Diabetes in Obese Subjects). *Endocr Pract.*; 12 Suppl 1: 31-3.
- Sonagra, A.D.; Dattatreya. KT. and Murthy, D.S. (2012):** Serum ldh, alp and uric acid in hypertensive disorders of pregnancy. *International Journal of Pharmacy and Biological Sciences*; 2(3); 201-9.
- Spencer, K.; Cowans, N.J. and Chefetz, I. (2007):** First trimester maternal serum PP-13, PAPP-A and second trimester uterine artery Doppler pulsatility index as

markers of pre-eclampsia. *Ultrasound, Obstet. Gynecol.*; 28: 700-6.

Spina, V.; Aleandri, V. and Morini, F. (2007): The impact of the factor V Leiden mutation on pregnancy. *Hum. Reprod.*; 6: 301–6.

Stepan, H.; Krämer, Thomas, Faber, Renaldo, A. and Walther, T. (2007): Maternal Plasma Concentrations of Soluble Endoglin in Pregnancies with Intrauterine Growth Restriction. *The Endocrine Society.*; 92(7): 2831-4.

Stephanie, A.; Rosen, M.D.; Shakil, H. and Crookston, M.D. (2007): Spontaneous Subcapsular Liver Hematoma Associated With Pregnancy. *Am. J. Surg.*; 146: 680-2.

Stepien, M.; Wlazel, R.N. and Paradowski, M. (2012): Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study. *Archives of medical science: AMS.*; 8(3): 431–6.

Steppan, C.M.; Bailey, S.T.; Bhat, S.; Brown, E.J.; Banerjee, R.R.; Wright, C.M.; Patel, H.R.; Ahima, R.S. and Lazar, M.A. (2001): The hormone resistin links obesity to diabetes. *Nature*; 409: 307–12.

Swinburn, B.A.; Carey, D.; Hills, A.P.; Hooper, M.; Marks, S. and Proietto, J. (2005): Effect of orlistat on cardiovascular disease risk in obese adults. *Diabetes Obes Metab.*; 7(3): 254-62.

- Tan, BK.; Adya, R.; Farhatullah, S.; Lewandowski, K.C.; O'Hare, P. and Lehnert, H. (2008):** Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. *Diabetes*; 57(4): 801-8.
- Thadhani, R.L.; Jhonson, R.J. and Karumanchi, S.A. (2005):** Hypertension during pregnancy: a disorder begging for pathophysiological support. *Hypertension*.; 46: 1250-1.
- Thangaratinam, S.; Coomarasamy, A. and O'Mahony, F.(2009):** Estimation of proteinuria as a predictor of complications of preeclampsia: a systematic review. *BMC Medicine*; 7: 10.
- Tilg, H. and Moschen, A.R. (2008):** Inflammatory mechanisms in the regulation of insulin resistance. *Mol Med*.; 14(3-4): 222.
- Toruner, F.; Altinova, A.E. and Karakoc, A. (2008):** Risk factors for cardiovascular disease in patients with subclinical hypothyroidism. *Adv Ther*.; 25(5): 430–7.
- Troendle, J.; Zhang, J. F. and Levine, R. J. (2008):** Risks of hypertensive disorders in the second pregnancy. *Paediatric and Perinatal Epidemiology*; 15: 226-31.
- Tsukimori, K.; Nakano, H. and Wake, N. (2007):** Difference in neutrophil superoxide generation during pregnancy

between pre-eclampsia and essential hypertension. *Hypertension*; 49: 1436-41.

Ueki, K. and Khan, R.C. (2000): Biochemistry of insulin action. *Diabetes mellitus in fundamental and clinical text* (2nd edition), Leroith D., Olefsky J.M. Lippincott and Williams (eds). Awolter Kluwer, Philadelphia; 183-91.

Unek, I.T.; Bayraktar, F. and Solmaz D. (2010): Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. *Metabolism*; 59(3): 305–13.

Uruska, A.; Araszkiwicz, A.; Zozulinska-Ziolkiewicz, D.; Uruski, P. and Wierusz-Wysocka, B. (2010): Insulin resistance is associated with microangiopathy in type 1 diabetic patients treated with intensive insulin therapy from the onset of disease. *Exp Clin Endocrinol Diabetes*; 118(8): 478-84.

Valera, R.L.; Mutter, W.P. and Wolf, M. (2009): First trimester placental growth factor and soluble fms-like tyrosine kinase1 and risk of pre-eclampsia. *J. Clin. Endocrinol. Metab.*; 89: 770-5.

Van Den Boogaard, E.; Vissenberg, R.; Land, J. A.; Van Wely, M.; Van Der Post, J. A. M.; Goddijn, M. and Bisschop, P.H. (2011): "Significance of (sub) clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: A systematic review". *Human Reproduction Update*; 17 (5): 605–19.

- van Raalte, D.H.; Brands, M. and van der Zijl, N.J. (2011):** Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. *Diabetologia*; 54(8): 2103-12.
- Vatten, L.J. and Skjaerven, R. (2010):** Is pre-eclampsia more than one disease? *J. Obstet. Gynecol.*; 111: 298-302.
- Venkatesha, S.; Toporsian, M. and Lam, C. (2007):** Soluble endoglin contributes to the pathogenesis of pre-eclampsia. *Nat. Med.*; 12: 642–9.
- Verma, S.; Li, S.H.; Wang, C.H.; Fedak, P.W.; Li, R.K. and Weisel, R.D. (2003):** Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. *Circulation*; 108(6):736-40.
- Vicent, D.; Ilany, J.; Kondo, T.; Naruse, K.; Fisher, S.J. and Kahn, C.R. (2008):** The role of endothelial insulin signaling in the regulation of vascular tone. *J. Clin. Invest*; 111: 1373-80.
- Von Dadelszen, P.; Magee, L.A. and Roberts, J.M. (2003):** Subclassification of pre-eclampsia. *Hypertens.*; 22: 143-8.
- Von Dadelszen, P. and Magee, L.A. (2010):** Could an infectious trigger explain the differential maternal response to the shared placental pathology of pre-eclampsia and normotensive intrauterine growth restriction? *Acta. Obstet. Gynecol. Scand.*; 81: 642-8.

von Dadelszen, P.; Payne, B.; Li, J.; Ansermino, J.M.; Broughton, Pipkin, F. and Côté, A.M. (2011): Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. *Lancet*; 377(9761): 219-27.

Wallace, T.M.; Levy, J.C. and Matthews, D.R. (2004): Use and Abuse of HOMA modeling. *Diabetes Care*; 27: 1487–95.

Wang, B.; Hasan, M.K.; Alvarado, E.; Yuan, H.; Wu, H. and Chen, W.Y. (2010): NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. *Oncogene*; 30: 907-21.

Weisman, J.; Ben-Haroush, A.; Lahav, J. and Sullivan, M. (2008): Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Pre-eclampsia. *Vascular Disease Prevention.*; (1): 101-7.

Wen, S.W.; Demissie, K.; Yang, Q. and Walker, M.C. (2009): Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies. *Am. J. Obstet. Gynecol.*; 191: 254-8.

White, D.L.; Ratziu, V. and El-Serag, H.B. (2008): Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. *J Hepatol*; 49: 831–44.

Wierzbicki, A.S.; Purdon, S.D.; Hardman, T.C.; Kulasegaram, R. and Peters, BS. (2008): HIV lipodystrophy and its metabolic consequences: implications for clinical practice. *Curr Med Res Opin.*; 24(3): 609-24.

- Wilson P.W. and Kannel, W.B. (2002):** Obesity, diabetes and risk of cardiovascular disease in the elderly. *Am. J. Geriatr. Cardiol.* Mar-Apr; 11(2): 119-123.
- Xia, Y.; Ramin, S.M. and Kellems, R.E. (2007):** Potential Roles of Angiotensin Receptor-Activating Autoantibody in the Pathophysiology of Preeclampsia. *Hypertension*; 50(2): 269-75.
- Yang, R.Z.; Huang, Q.; Xu, A.; McLenithan, J.C.; Eisen J. A. and Shuldiner A.R. (2003):** Comparative studies of resistin expression and phylogenomics in human and mouse. *Biochem. Biophys. Res. Commun.*; (310) 3:927-35.
- Young, B.C.; Levine, R.J. and Karumanchi, S.A.F. (2010):** Pathogenesis of Pre-eclampsia. *Annual Review of Pathology: Mechanisms of Disease*; 5: 173-92.
- Yura, S.; Sagawa, N. and Itoh, H. (2003):** Resistin is expressed in the human placenta. *J. Clin. Endocrinol. Metab.*; 88: 1394–7.
- Zwahlen, M.; Gerber, S. and Bersinger, N.A. (2006):** First trimester markers for pre-eclampsia: Placental Vs non-placental protein serum levels. *Gynecol. Obstet. Invest.*; 63: 15-21.
- Zweig, M.H. and Campbell, G. (1993):** Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clin. Chem.*; 39: 561-77.

المخلص العربي

يعتبر مرض تسمم الحمل من أخطر الأمراض التي تسبب الوفاة للمرأة الحامل و الأطفال حديثي الولادة علي مستوي العالم، كما يؤثر هذا المرض سلباً علي جميع أجهزة الجسم.

تسمم الحمل هو أحد الأسباب الرئيسية للوفاة في الفترة المحيطة بالولادة للأمهات، و يحدث في ٦-٨ ٪ من حالات الحمل، ويسبب تسمم الحمل في الام اختلالا وظيفيا متعددًا بما في ذلك الفشل الكلوي و الفشل الكبدي و أمراض تجلط الدم واضطرابات الجهاز العصبي المركزي، أما في الجنين فإنه قد يؤدي إلى تقليل نمو الجنين أو الولادة المبكرة أو الوفاة قبل الولادة.

وقد اثبتت الابحاث أن مجموعة الأديبوكين لها دورا هاما في حدوث تسمم الحمل من خلال دورها في حدوث إلتهابتصلب الشرايين ومقاومة الأنسولين. ولذلك فان مجموعة الأديبوكين يكون لها تأثير مباشر أو غير مباشر على وظيفة الخلايا المبطنة للاوعية الدموية في المشيمة.

يتم تعريف مقاومة الانسولين علي انه عدم قدرة كمية محددة من الانسولين علي زيادة امتصاص الجلوكوز والاستفادة منه وتحدد علاقة توازن الجلوكوز للأنسولين بمجموعة من المعادلات الغير خطية البسيطة. يعبر عنها رياضيا بالمعادلة الاتية : الجلوكوز(صايم) × الانسولين(صايم) / ٢٢,٥.

يعتبر الرزيستين هو احد البروتينات التي تنتمي الي عائلة الاديبوكين وهو من الهرمونات الغنية بالسيستين والذي يفرز بشكل رئيسي من قبل الخلايا الدهنية للإنسان وهذا الهرمون يقلل ادخال الجلوكوز للخلايا الدهنية ويزيد تركيز الجلوكوز في البلازما وبالتالي يقلل من حساسية الأنسولين. ويفرز رزيستين من

المشيمة البشرية ويزداد مستواه في مصل الام في الثلث الثالث من الحمل ، مما يشير إلى دور المشيمة في حدوث مقاومة للأنسولين أثناء الحمل. ومع ذلك فإن التغيرات في مستوى مصل ريزستين في الحمل السكري تزال غير واضحة.

وفي محاولة لتقييم الدور الذي يلعبه الريزستين الموجود في بلازما الحوامل المصابات بمرض تسم الحمل، فقد تم قياسه باستخدام الطريقة الإنزيمية المناعية في بلازما ستين سيده حامل مصابة بمرض تسم الحمل وقد تم تقسيم المرضى إلى مجموعتين، الأولى ثلاثون سيده حامل مصابة بتسم الحمل بدرجة بسيطة والمجموعة الثانية تتكون من ثلاثين سيده حامل مصابة بتسم الحمل بدرجة حادة وقد تمت مقارنة النتائج مع خمسة عشر سيده حامل من الأصحاء وخمسة عشر من الإناث الأصحاء غير الحوامل مطابقات لمجموعة المرضى من حيث السن.

وقد أظهرت النتائج وجود زيادة ذات دلالة إحصائية كبيرة في نسبة كلا منالريزستينو علاقة توازن الجلوكوز للأنسولين في البلازما في حالات تسم الحمل مقارنة بالحوامل الأصحاء، كذلك اظهرت النتائج ارتباط زيادة الريزستين و علاقة توازن الجلوكوز للأنسولين ارتباطاً طردياً مع شدة المرض، حيث كان مستوى الريزستين و علاقة توازن الجلوكوز للأنسولين أعلى كثيراً في الحالات الشديدة مقارنة بالحالات البسيطة. كما أثبتت النتائج وجود ارتباط إيجابي بين نسبة كلا من الريزستين و علاقة توازن الجلوكوز للأنسولينوكلا من ضغط الدم الإنبساطى و ضغط الدم الإنقباضى وذلك في الحالات المصابة بمرض تسم الحمل.

وتبين أن أفضل قيمة للريزستين لتحديد ظهور المرض في السيدات الحوامل هي ٠١نانوجرام/مل، فهذه القيمة لها حساسية تشخيصية تصل ٨٨% وخصوصية تشخيصية تصل إلى ٩٧% وقيمة توقع إيجابية تساوى ٩٨% وقيمة

توقع سلبية تساوى ٨٠% ، بينما افضل قيمة لعلاقة توازن الجلوكوز للأنسلولين لتحديد ظهور المرض فى السيدات الحوامل هي ٢ ، فهذه القيمة لها حساسية تشخيصية تصل ٩٨% وخصوصية تشخيصية تصل إلى ٩٤% وقيمة توقع إيجابية تساوى ٩٨% وقيمة توقع سلبية تساوى ٩٦%.

وأيضاً تبين أن أفضل قيمة لتحديد شدة المرض للريزستينهي ١٧نانوجرام/مل، فهذه القيمة لها حساسية تشخيصية تصل إلى ٩٦% وخصوصية تشخيصية تصل إلى ٧٠% وقيمة توقع إيجابية تساوى ٧٦% وقيمة توقع سلبية تساوى ٩٥%. بينما افضل قيمة لعلاقة توازن الجلوكوز للأنسلولين لتحديد شدة المرض هي ٣,٧، فهذه القيمة لها حساسية تشخيصية تصل ٩٣% وخصوصية تشخيصية تصل إلى ٤٠% وقيمة توقع إيجابية تساوى ٦١% وقيمة توقع سلبية تساوى ٨٦%.

وعلى ذلك نستنتج أن هرمون الريزستين يعد مؤشراً معملياً جيداً من حيث الحساسية والخصوصية والكفاءة ليس فقط لتشخيص حالات تسمم الحمل و لكن أيضاً لتحديد درجة شدة المرض مما يساعد فى إتباع إستراتيجيات جديدة فى علاج المرض وبالتالي خفض نسبة الوفيات بين الأطفال والأمهات.
